The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Emerging CAR-T therapies for T-cell lymphoma
Emmanuel Bachy, MD, PhD, Lyon Sud Hospital Center, Lyon, France, outlines novel promising CAR-T therapies in development for the treatment of T-cell lymphoma, including a CAR-T directed against the constant fraction of the T-cell receptor (TCR) and an allogeneic product directed against CD70. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
